Ratings Gulf Pharmaceutical Industries

Equities

JULPHAR

AEG000201018

Market Closed - Abu Dhabi Securities Exchange Other stock markets 06:44:30 2024-07-12 am EDT			5-day change	1st Jan Change
0.811 ^AED	-0.37%		-0.73%	+5.46%

May. 15	Julphar Resumes Trading on Abu Dhabi Bourse	MT
May. 15	Gulf Pharmaceutical Industries Turns to Q1 Profit; Revenue Tumbles	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The group shows a rather high level of debt in proportion to its EBITDA.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
GULF PHARMACEUTICAL INDUSTRIES	+5.46%	255M		C+
MERCK KGAA	+7.04%	73.13B		A
KYOWA KIRIN CO. LTD.	+31.10%	10.38B		A-
YUHAN CORPORATION	+37.94%	5.16B		B-
SK BIOPHARMACEUTICALS CO., LTD.	-17.33%	4.73B		A-
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+21.49%	3.81B		-
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+24.92%	2.26B	-	-
BETTA PHARMACEUTICALS CO., LTD.	-36.84%	1.88B		C-
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-43.31%	1.77B		-
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders